IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re	Application of	:	
Griffe	ey et al.		Group Art Unit: Not Assigned Yet
For:		of Ligand Affinity for RNA g Mass Spectrometry	Examiner: Not Assigned Yet
	I	DECLARATION AND POWI	ER OF ATTORNEY
As a b	elow named in	ventor, I hereby declare that:	
My re	sidence, post o	ffice address and citizenship are	e as stated below next to my name; and
origin	eve that I am the al, first and join med and for wh	nt inventor (if plural names are	or (if only one name is listed below) or an listed below) of the subject matter which
		Utility Patent	Design Patent
is sou	ght on the inve	ntion, whose title appears above	e, the specification of which:
	⊠	is attached hereto.	as Serial No
		said application having been	amended on
			he contents of the above-identified among amendment referred to above.
			at and Trademark Office all information lication in accordance with 37 CFR §
I here	by claim foreig	n priority benefits under 35 U.S	S.C. § 119(a-d) of any foreign


application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of





DOCKET NO. IBIS-0261

rity med ('d)	Country	Serial Number	Date Filed
		_	
w and, losed i 5 U.S. ce all i ch beca	insofar as the subject reaction the prior United State C. § 112, I acknowledge information known to be ame available between the state of the state	matter of each of the claim es application in the mana e the duty to disclose to the e material to patentabilith the filing date of the prio	nited States application(s) listed ms of this application is not her provided by the first paragrap the U.S. Patent and Trademark y as defined in 37 CFR § 1.56 r application and the national or
w and, losed i 5 U.S. ce all i ch beca	insofar as the subject renth in the prior United State C. § 112, I acknowledge information known to be	matter of each of the claim es application in the mana e the duty to disclose to the e material to patentabilith the filing date of the prio	ms of this application is not ner provided by the first paragrap the U.S. Patent and Trademark y as defined in 37 CFR § 1.56
w and, losed i 5 U.S. ce all i ch beca	insofar as the subject reaction the prior United State C. § 112, I acknowledge information known to be ame available between the particular filing date of the state of the st	matter of each of the claims application in the manner the duty to disclose to the material to patentability the filing date of the priority application:	ms of this application is not ner provided by the first paragraph the U.S. Patent and Trademark y as defined in 37 CFR § 1.56 r application and the national or
w and, losed i 5 U.S. ce all i ch beca	insofar as the subject reaction the prior United State C. § 112, I acknowledge information known to be ame available between the particular filing date of the state of the st	matter of each of the claims application in the manner the duty to disclose to the material to patentability the filing date of the priority application:	ms of this application is not ner provided by the first paragraph the U.S. Patent and Trademark y as defined in 37 CFR § 1.56 r application and the national or
w and, losed i 5 U.S. ce all i ch beca	insofar as the subject reaction the prior United State C. § 112, I acknowledge information known to be ame available between the particular filing date of the state of the st	matter of each of the claims application in the manner the duty to disclose to the material to patentability the filing date of the priority application:	ms of this application is not ner provided by the first paragraph the U.S. Patent and Trademark y as defined in 37 CFR § 1.56 r application and the national or
w and, losed i U.S. ce all i ch beca interr	n the prior United State C. § 112, I acknowledge Information known to be Interested and in the state Interested a state Interes	matter of each of the claimes application in the manner of the duty to disclose to the ematerial to patentability the filing date of the priority application: Date Filed	ms of this application is not ner provided by the first paragraph the U.S. Patent and Trademark y as defined in 37 CFR § 1.56 r application and the national or



John W. Caldwell

Registration No. 28,937

Joseph Lucci

Registration No. 33,307

of WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP, One Liberty Place - 46th Floor, Philadelphia, Pennsylvania 19103 and

Herb Boswell

Registration No. 27,311

Laurel Bernstein

Registration No. 37,280

Robert S. Andrews

Registration No. 44,508

April Logan

Registration No. 33,950

of ISIS PHARMACEUTICALS, INC., 2292 Faraday Avenue, Carlsbad, California 92008

Address all telephone calls and correspondence to:

John W. Caldwell WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP

One Liberty Place - 46th Floor


Philadelphia PA 19103

Telephone No.: (215) 568-3100 Facsimile No.: (215) 568-3439

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.







Name: Steve Hofstadler	
Mailing Address: 5014 Viewridge Way Oceanside, CA 92056	Signature
	Date of Signature:
City/State of Actual Residence: Oceanside, CA	Citizenship: United States of America

Name: Jared Drader	
Mailing Address:	Signature
City/State of Actual Residence:	Date of Signature:
	Citizenship:





DOCKET NO. IBIS-0261 Name: Kristen Lowery Signature Mailing Address: Date of Signature: City/State of Actual Residence: Citizenship:

Name: Mohan Venkatraman	
Mailing Address: 7042 Via Cabana Carlsbad, CA 92009	Signature
City/State of Actual Residence: Carlsbad, CA	Date of Signature:
	Citizenship: Indian

Applicant or Patentee: Griffey et al.

Serial No.: Not Yet Known Attorney's Docket No.: IBIS-0261

Date Filed: Herewith

F r: Optimization of Ligand Affinity for RNA Targets Using Mass Spectrometry

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) and 1.27© - SMALL BUSINESS CONCERN

I hereby declare that I am:

- () the owner of the small business concern identified below:
- (X) an official empowered to act on behalf of the concern identified below:

NAME OF CONCERN: ADDRESS OF CONCERN: ISIS Pharmaceuticals, Inc. 2292 Faraday Avenue Carlsbad, CA 92008

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that: (1) the number of employees of the concern, including those of its affiliates, does not exceed 500 persons; and (2) the concern has not assigned, granted, conveyed, or licensed, and is under no obligation under contract or law to assign, grant, convey, or license, any rights in the invention to any person who could not be classified as an independent inventor if that person had made the invention, or to any concern which would not qualify as a small business concern or a nonprofit organization under this section.

For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled

by inventor(s) Richard Griffey; Steve Hofstadler; Jared Drader; Kristen Lowery and Mohan Venkatraman

described in Optimization of Ligand Affinity for RNA Targets Using Mass Spectrometry

(X)	specification	filed	herewith.
-----	---------------	-------	-----------

() application serial no	o, filed
--------------------------	----------

()	patent no.	, issued
---	---	------------	----------

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights in the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9© if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required for each named person, concern or organization having rights to the invention averring to their status as small entities. (37 **CFR 1.27**)

FULL NAME:

ADDRESS:

() INDIVIDUAL () SMALL BUSINESS CONCERN () NONPROFIT ORGANIZATION

FULL NAME:

ADDRESS:

() INDIVIDUAL () SMALL BUSINESS CONCERN () NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING TITLE OF PERSON SIGNING

ADDRESS OF PERSON-SIGNING

SIGNATURE

72B. 07.

B. Lynne Parshall, Esq. **Executive Vice President and Chief Financial Officer** 2292 Faraday Avenue Carlsbad, CA 92008